Methylprednisolone Sodium SuccinateCAS# 2375-03-3 |
- Meprednisone
Catalog No.:BCC4893
CAS No.:1247-42-3
- Hydrocortisone
Catalog No.:BCN2192
CAS No.:50-23-7
- Prednisolone
Catalog No.:BCC4830
CAS No.:50-24-8
- Desonide
Catalog No.:BCC4967
CAS No.:638-94-8
- Fluticasone propionate
Catalog No.:BCC4907
CAS No.:80474-14-2
- Methylprednisolone
Catalog No.:BCC2256
CAS No.:83-43-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 2375-03-3 | SDF | Download SDF |
| PubChem ID | 23680530 | Appearance | Powder |
| Formula | C26H33NaO8 | M.Wt | 496.53 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Methylprednisolone sodium succinate; 6-Methylprednisolone succinate sodium | ||
| Solubility | DMSO : ≥ 25 mg/mL (50.35 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | sodium;4-[2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoate | ||
| SMILES | CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)[O-])O.[Na+] | ||
| Standard InChIKey | FQISKWAFAHGMGT-SGJOWKDISA-M | ||
| Standard InChI | InChI=1S/C26H34O8.Na/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24;/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31);/q;+1/p-1/t14-,16-,17-,19-,23+,24-,25-,26-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Methylprednisolone Sodium Succinate Dilution Calculator
Methylprednisolone Sodium Succinate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.014 mL | 10.0699 mL | 20.1398 mL | 40.2795 mL | 50.3494 mL |
| 5 mM | 0.4028 mL | 2.014 mL | 4.028 mL | 8.0559 mL | 10.0699 mL |
| 10 mM | 0.2014 mL | 1.007 mL | 2.014 mL | 4.028 mL | 5.0349 mL |
| 50 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 0.8056 mL | 1.007 mL |
| 100 mM | 0.0201 mL | 0.1007 mL | 0.2014 mL | 0.4028 mL | 0.5035 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
6α-Methylprednisolone 21-hemisuccinate sodium salt is a glucocorticoid of slightly longer half-life than that of Prednisolone. It has potential uses in antiinflammatory agents.
- Rivulobirin E
Catalog No.:BCN5090
CAS No.:237407-59-9
- 4-Amino-3-hydroxybenzoic acid
Catalog No.:BCC8681
CAS No.:2374-03-0
- trans-3'-O-Benzoyl-4'-O-methylkhellactone
Catalog No.:BCN6921
CAS No.:23733-95-1
- trans-Methylkhellactone
Catalog No.:BCN6919
CAS No.:23733-92-8
- 6-Hydroxy-4-Methylcoumarin
Catalog No.:BCC9206
CAS No.:2373-31-1
- Chebulic acid
Catalog No.:BCN3260
CAS No.:23725-05-5
- Nardosinone
Catalog No.:BCN2324
CAS No.:23720-80-1
- Platycoside E
Catalog No.:BCN6385
CAS No.:237068-41-6
- Damascenone
Catalog No.:BCN8355
CAS No.:23696-85-7
- Olaquindox
Catalog No.:BCN2538
CAS No.:23696-28-8
- Boc-Ser(Bzl)-OH
Catalog No.:BCC3442
CAS No.:23680-31-1
- Levosulpiride
Catalog No.:BCC4463
CAS No.:23672-07-3
- 4-Aminopyrazolo[3,4-d]pyrimidine
Catalog No.:BCC8690
CAS No.:2380-63-4
- Homovanillyl alcohol
Catalog No.:BCN7173
CAS No.:2380-78-1
- 6-Hydroxyindole
Catalog No.:BCN8310
CAS No.:2380-86-1
- Pogostone
Catalog No.:BCN2696
CAS No.:23800-56-8
- Hinesol
Catalog No.:BCC9232
CAS No.:23811-08-7
- Trichokaurin
Catalog No.:BCN4851
CAS No.:23811-50-9
- Ac-Trp-OEt
Catalog No.:BCC3110
CAS No.:2382-80-1
- Ambroxol HCl
Catalog No.:BCC5067
CAS No.:23828-92-4
- Liensinine perchlorate
Catalog No.:BCN6335
CAS No.:2385-63-9
- Ethyl2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate
Catalog No.:BCC8979
CAS No.:238749-50-3
- Tosedostat (CHR2797)
Catalog No.:BCC2309
CAS No.:238750-77-1
- Zapotinin
Catalog No.:BCC9192
CAS No.:14813-20-8
A Placebo-Controlled, Prospective, Randomized Clinical Trial of Polyethylene Glycol and Methylprednisolone Sodium Succinate in Dogs with Intervertebral Disk Herniation.[Pubmed:26520829]
J Vet Intern Med. 2016 Jan-Feb;30(1):206-14.
BACKGROUND: Acute intervertebral disk herniation (IVDH) is a common cause of spinal cord injury in dogs and currently there is no proven medical treatment to counter secondary injury effects. Use of Methylprednisolone Sodium Succinate (MPSS) or polyethylene glycol (PEG) as neuroprotectants is advocated but controversial because neither treatment has been tested in placebo-controlled, randomized, blinded trials in dogs. HYPOTHESIS: Polyethylene glycol will improve the outcome of severe spinal cord injury caused by IVDH compared to MPSS or placebo. ANIMALS: Client-owned dogs with acute onset of thoracolumbar IVDH causing paralysis and loss of nociception for <24 hours. METHODS: Dogs were randomized to receive MPSS, PEG, or placebo; drugs appeared identical and group allocation was masked. Drug administration was initiated once the diagnosis of IVDH was confirmed and all dogs underwent hemilaminectomy. Neurologic function was assessed 2, 4, 8, and 12 weeks postoperatively using an open field gait score (OFS) as the primary outcome measure. Outcomes were compared by the Wilcoxon rank sum test. RESULTS: Sixty-three dogs were recruited and 47.6% recovered ambulation. 17.5% developed progressive myelomalacia but there was no association with group. There was no difference in OFS among groups. Although full study power was not reached, conditional power analyses indicated the futility of continued case recruitment. CONCLUSIONS: This clinical trial did not show a benefit of either MPSS or PEG in the treatment of acute, severe thoracolumbar IVDH when used as adjunctive medical treatment administered to dogs presenting within 24 hours of onset of paralysis.
Methylprednisolone sodium succinate reduces BBB disruption and inflammation in a model mouse of intracranial haemorrhage.[Pubmed:27746369]
Brain Res Bull. 2016 Oct;127:226-233.
Inflammation and disruption of the blood-brain barrier (BBB) cause oedema and secondary brain injury after intracranial haemorrhage (ICH), which is closely related to patient prognosis. Methylprednisolone Sodium Succinate (MPSS), a well-known immunosuppressive agent, is widely applied in many diseases to inhibit inflammation. In this study, we investigated the effect of MPSS on inflammation and disruption of the BBB in a model mouse of ICH. ICH was induced by injecting collagenase into the right striatum of male C57/BL mice. Permeability of BBB was measured with Evans Blue assay and brain oedema was detected by measurement of brain water content. Expressions of NF-kappaB, TLR4, occludin, ZO-1, IL-1beta, TNF-alpha, Bax, and Bcl-2 were determined by Western Blot. Neutrophils, microglia were measured by immunohistochemistry staining, neuronal apoptosis was measured by TUNEL and NeuN co-stained. Administration of MPSS post-ICH significantly reduced permeability of the BBB and brain oedema and upregulated expression of ZO-1 and Occludin. MPSS inhibited inflammatory responses, including reducing proinflammatory cytokines (IL-1beta, TNF-alpha), suppressing infiltration of neutrophils and activation of microglia. This was accompanied by attenuated activation of the TLR4/NF-kappaB signalling pathway. In addition, MPSS reduced neuronal apoptosis through increasing Bcl-2 expression and reducing Bax expression. MPSS suppressed inflammatory responses, attenuated disruption of the BBB and reduced neuronal apoptosis, contributing to reduction of secondary brain injury after ICH. These results suggest that MPSS may be a potential therapy for ICH.
Localized delivery of methylprednisolone sodium succinate with polymeric nanoparticles in experimental injured spinal cord model.[Pubmed:26895158]
Pharm Dev Technol. 2017 Dec;22(8):972-981.
With important social and economic consequences, spinal cord injuries (SCIs) still exist among major health problems. Although many therapeutic agents and methods investigated for the treatment of acute SCI, only high dose methylprednisolone (MP) is being used currently in practice. Due to the serious side effects, high dose systemic MP administration after SCI is a critical issue that is mostly considered controversial. In our study, it is aimed to develop a nanoparticle-gel combined drug delivery system for localization of MP on trauma site and eliminating dose-dependent side effects by lowering the administered dose. For this purpose, methyl prednisolone sodium succinate (MPSS) loaded polycaprolactone based nanoparticles were developed and embedded in an implantable fibrin gel. The effects of MPSS delivery system are evaluated on an acute SCI rat model, by quantification the levels of three inflammatory cytokines (interleukin-1beta, interleukin-6 and caspase-3) and assessment of the damage on ultrastructural level by transmission electron microscopy. Developed NP-gel system showed very similar results with systemic high dose of MPSS. It is believed that developed system may be used as a tool for the safe and effective localized delivery of several other therapeutic molecules on injured spinal cord cases.
Efficacy of methylprednisolone sodium succinate for injection (postotic injection) on the auditory threshold and speech recognition rate of sudden deafness patients.[Pubmed:26550378]
Int J Clin Exp Med. 2015 Aug 15;8(8):14110-4. eCollection 2015.
OBJECTIVE: To investigate the effect of injecting the methylprednisolone in the ear for the sudden deafness and the improvement of speech discrimination test. METHODS: 50 inpatients with a sudden hearing loss were recruited. Inject the methylprednisolone in the subperiosteal of the ear which is 0.5 cm distance to the ear ditch every three days. Methylprednisolone was placed for fifteen days. Simultaneously vasodilation, neurotrophic, thrombolysis and insulin hypoglycemia were administered in all patients. Pure tone test and speech discrimination test were conducted at Days 7 & 14 after intervention. RESULTS: The outcome was as follows: cure (n = 8), efficacy (n = 9), effect (n = 18) and no effect (n = 15) respectively. The overall effective rate of 70%. The improvement of pure tone threshold and speech discrimination had significant statistical difference (P < 0.05). CONCLUSION: The therapy of postaural methylprednisolone injection can decrease pure tone threshold effectively and increased speech discrimination with a sudden hearing loss.
